PROQR THERAPEUTICS Valuation
| 0PQ Stock | EUR 1.87 0.04 2.19% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. PROQR THERAPEUTICS holds a recent Real Value of €1.62 per share. The prevailing price of the company is €1.87. Our model determines the value of PROQR THERAPEUTICS from reviewing the company fundamentals such as shares outstanding of 71.43 M, and Return On Equity of -0.75 as well as analyzing its technical indicators and probability of bankruptcy. In general, most investors support locking in undervalued entities and disposing overvalued entities since, at some point in time, asset prices and their ongoing real values will merge together.
Overvalued
Today
Please note that PROQR THERAPEUTICS's price fluctuation is dangerous at this time. Calculation of the real value of PROQR THERAPEUTICS is based on 3 months time horizon. Increasing PROQR THERAPEUTICS's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for PROQR THERAPEUTICS EO 04 is useful when determining the fair value of the PROQR stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of PROQR THERAPEUTICS. Since PROQR THERAPEUTICS is currently traded on the exchange, buyers and sellers on that exchange determine the market value of PROQR Stock. However, PROQR THERAPEUTICS's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.87 | Real 1.62 | Hype 1.87 | Naive 1.89 |
The real value of PROQR Stock, also known as its intrinsic value, is the underlying worth of PROQR THERAPEUTICS Company, which is reflected in its stock price. It is based on PROQR THERAPEUTICS's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of PROQR THERAPEUTICS's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence PROQR THERAPEUTICS's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of PROQR THERAPEUTICS EO 04 helps investors to forecast how PROQR stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of PROQR THERAPEUTICS more accurately as focusing exclusively on PROQR THERAPEUTICS's fundamentals will not take into account other important factors: PROQR THERAPEUTICS Total Value Analysis
PROQR THERAPEUTICS EO 04 is presently estimated to have takeover price of 0 with market capitalization of 207.46 M, debt of 34.28 M, and cash on hands of 75.84 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the PROQR THERAPEUTICS fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
| 0 | 207.46 M | 34.28 M | 75.84 M |
PROQR THERAPEUTICS Investor Information
About 21.0% of the company shares are owned by insiders or employees . The company recorded a loss per share of 0.92. PROQR THERAPEUTICS had not issued any dividends in recent years. ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands. PROQR THERAPEUTICS is traded on Frankfurt Stock Exchange in Germany. For more info on PROQR THERAPEUTICS EO 04 please contact Daniel Boer at 31 88 166 7000 or go to http://www.proqr.com.PROQR THERAPEUTICS Asset Utilization
One of the ways to look at asset utilization of PROQR is to check how much profit was generated for every dollar of assets it reports. PROQR THERAPEUTICS holds a negative application of assets of -0.26 pct., losing €0.002628 for each euro of assets held by the company. Ineffective asset utilization implies the company is being less efficient with each euro of assets it holds. Put it differently, asset utilization of PROQR THERAPEUTICS EO 04 shows how unsuccessful it operates for each euro spent on its assets.PROQR THERAPEUTICS Ownership Allocation
PROQR THERAPEUTICS has a total of 71.43 Million outstanding shares. PROQR THERAPEUTICS has large amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.PROQR THERAPEUTICS Profitability Analysis
The company reported the revenue of 3.93 M. Net Loss for the year was (46.56 M) with profit before overhead, payroll, taxes, and interest of 2.4 M. Profitability |
| Values |
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates PROQR THERAPEUTICS's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in PROQR THERAPEUTICS and how it compares across the competition.
About PROQR THERAPEUTICS Valuation
The stock valuation mechanism determines the current worth of PROQR THERAPEUTICS EO 04 on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of PROQR THERAPEUTICS EO 04. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of PROQR THERAPEUTICS based exclusively on its fundamental and basic technical indicators. By analyzing PROQR THERAPEUTICS's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of PROQR THERAPEUTICS's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of PROQR THERAPEUTICS. We calculate exposure to PROQR THERAPEUTICS's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to PROQR THERAPEUTICS's related companies.ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands. PROQR THERAPEUTICS is traded on Frankfurt Stock Exchange in Germany.
8 Steps to conduct PROQR THERAPEUTICS's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates PROQR THERAPEUTICS's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct PROQR THERAPEUTICS's valuation analysis, follow these 8 steps:- Gather financial information: Obtain PROQR THERAPEUTICS's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine PROQR THERAPEUTICS's revenue streams: Identify PROQR THERAPEUTICS's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research PROQR THERAPEUTICS's industry and market trends, including the size of the market, growth rate, and competition.
- Establish PROQR THERAPEUTICS's growth potential: Evaluate PROQR THERAPEUTICS's management, business model, and growth potential.
- Determine PROQR THERAPEUTICS's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate PROQR THERAPEUTICS's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in PROQR THERAPEUTICS EO 04. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for PROQR Stock analysis
When running PROQR THERAPEUTICS's price analysis, check to measure PROQR THERAPEUTICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PROQR THERAPEUTICS is operating at the current time. Most of PROQR THERAPEUTICS's value examination focuses on studying past and present price action to predict the probability of PROQR THERAPEUTICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PROQR THERAPEUTICS's price. Additionally, you may evaluate how the addition of PROQR THERAPEUTICS to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |